Jorge Conde News Today

BioPharma

Is Ozzy Osbourne a mutant? According to some serious scientists, the answer is yes. A group of researchers from Massachusetts claimed that Osbourne's unusua

BioPharma

Adding predictive LTV to your startup’s marketing strategy may literally help you stop throwing money away.

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

BioPharma

Cort da a conocer los proyectos de creación que apoyará este 2021 La directora del Solleric, Aina Bauzà; Juan Carlos Rego (jurado); los artistas Leticia Muñoz y José Fiol; el regidor Antoni Noguera, y Francisco Copado, director de la Fundació Miró. Las obras de los artistas Jorge Conde, José Fiol y Leticia Muñoz, y el proyecto de investigación de Andrea Corrales, han ganado la convocatoria del Ajuntament de Palma para contratar proyectos de creación e investigación artística, que s...

Students, teachers with COVID-19 vaccines can ditch masks in class, CDC says News 12 Staff Updated on: Jul 10, 2021, 2:52am Vaccinated students and teachers can ditch their masks in class, according to new guidancefrom the Centers for Disease Control and Prevention. Schools in Peekskill are already adapting their rules beginning Monday.  Jorge Condes son is in the Peekskill School District and will be turning 12 soon. He says the plan is to get him vaccinated this summer to get him out of a m...

Dyno Therapeutics, Inc., a Cambridge, Mass.-based biotechnology company applying artificial intelligence (AI) to gene therapy, raised $100m in Series A financing. The round was led by Andreessen Horowitz, with participation from a select syndicate of new investors including Casdin Capital, GV, Obvious Ventures and Lux Capital. Founding investors Polaris Partners, CRV and KdT Ventures all participated in the round. As part of the Series A financing, Jorge Conde, General Partner at Andreessen H...

MedCity News Andreessen Horowitz leads $100M Series A round in Dyno and its gene therapy tech Dyno Therapeutics’ technology for designing viral vectors that deliver gene therapies has led to partnerships with Novartis, Sarepta Therapeutics, and Roche. With the Series A financing, the startup plans to expand its technology to address more tissue types, and potentially add more partners. Shares0 Improved AAV vector capsid for gene therapy engineered with a new machine-guided approach shows, i...